据最新一期美国癌症学会《临床癌症研究》杂志报道，厄洛替尼（Tarceva）可以抑制表皮生长因子发挥作用，而这种生长因子能够促进肺癌细胞生长。但是，较早时候的临床数据表明，这种药物只能对10%的肺癌患者有治疗效果，研究人员对这种情况既不能解释也无法解决。
加利福尼亚大学伯克利分校研究人员在最新临床研究中发现，如果同时使用塞来昔布与厄洛替尼（Tarceva），厄洛替尼（Tarceva）的患者适用人群明显扩大，对33%的肺癌患者有治疗效果。领导这项研究的卡伦•雷坎普在一份声明中说，将两种药物同时使用后，发现厄洛替尼（Tarceva）的患者适用人群显著扩大，“这表明塞来昔布帮助部分患者消除了对厄洛替尼（Tarceva）的抗药性”。
虽然仍不能解释出现这种情况的原因，但雷坎普认为这与塞来昔布的一些特殊性质有关。塞来昔布属于环氧化酶-2抑制剂，目前是一种用于治疗关节炎的处方药物。但在最近的研究中发现，塞来昔布能够抑制肿瘤周围血管再生，促进肿瘤细胞凋亡。美国食品和药物管理局2005年建议，应加强塞来昔布在癌症防治方面的临床测试。
仅美国每年就会新增17.3万名肺癌患者，其中16万名以上的患者会死于这种致命的疾病。
Clin Cancer Res. 2006 Jun 1;12(11):3381-8.
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.
Authors'' Affiliations: Department of Medicine, Division of Hematology/Oncology.
PURPOSE: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI)-resistant manner. Because preclinical data indicated that tumor COX-2 expression caused resistance to EGFR TKI, a phase I trial to establish the optimal biological dose (OBD), defined as the maximal decrease in urinary prostaglandin E-M (PGE-M), and toxicity profile of the combination of celecoxib and erlotinib in advanced non-small cell lung cancer was done. EXPERIMENTAL DESIGN: Twenty-two subjects with stage IIIB and/or IV non-small cell lung cancer received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib. Primary end points included evaluation of toxicity and determination of the OBD of celecoxib when combined with erlotinib. Secondary end points investigate exploratory biological markers and clinical response. RESULTS: Twenty-two subjects were enrolled, and 21 were evaluable for the determination of the OBD, toxicity, and response. Rash and skin-related effects were the most commonly reported toxicities and occurred in 86%. There were no dose-limiting toxicities and no cardiovascular toxicities related to study treatment. All subjects were evaluated on intent to treat. Seven patients showed partial responses (33%), and five patients developed stable disease (24%). Responses were seen in patients both with and without EGFR-activating mutations. A significant decline in urinary PGE-M was shown after 8 weeks of treatment, with an OBD of celecoxib of 600 mg bid. CONCLUSIONS: This study defines the OBD of celecoxib when combined with a fixed dose of EGFR TKI. These results show objective responses with an acceptable toxicity profile. Future trials using COX-2 inhibition strategies should use the OBD of celecoxib at 600 mg bid.
| 药品价格(单位:元) | ||||||
|
编号 |
药品名称 |
通用名 |
产地 |
规格 |
单位 |
参考价 |
| 121844 | 特罗凯 | 盐酸厄洛替尼片 | Schwarz Pharma Manufacturing Inc. | 150mg*30片 | 盒 | 19800 |
| *声明：以上价格仅作参考,实际价格以药房各分店为准。 | ||||||